Innovative Immune Therapy Approach Drives Buy Rating for TuHURA Biosciences

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on TuHURA Biosciences (HURA – Research Report), retaining the price target of $15.00.

Jason McCarthy has given his Buy rating due to a combination of factors surrounding TuHURA Biosciences’ innovative approach in treating Merkel cell carcinoma (MCC). The company is advancing its immune therapy candidate, IFx-2.0, in combination with pembrolizumab for first-line treatment of metastatic MCC. This novel therapy aims to enhance the overall response rate (ORR) significantly, potentially reaching 70% or higher, compared to the current standard of care.
The initiation of a Phase 1b/2a study targeting MCC of unknown primary origin (MCCUP) further underscores TuHURA’s strategic expansion into areas with unmet medical needs. This study will explore the feasibility of using radiologically delivered IFx-2.0 in patients with deep-seated tumors, potentially paving the way for broader applications in other tumor types resistant to checkpoint inhibitors. The promising potential of IFx-2.0 to improve treatment outcomes and the strategic clinical development plan contribute to McCarthy’s positive outlook on TuHURA’s stock.